
Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideo
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Don’t miss our latest news! Sign up today for our free newsletter.
By continuing to use our site, you agree to our Private Policy and Terms of Use.
A study in the journal Antiviral Therapy shows that HIVers often make a trade-off in deciding when to begin antiretroviral therapy between mortality risk and the potential drug toxicities and pill burden. Researchers polled HIVers as to when they'd prefer to begin antiretroviral therapy if delaying treatment for one year raised three-year mortality risks by up to 10%. Starting treatment to reduce mortality risks ''30% would always begin treatment early, even if mortality risks did not rise by waiting ''25% would always delay treatment, even if mortality risks rose 10% Starting treatment based on CD4-cell counts ''50% would start treatment when CD4-cell levels drop below 350 if waiting raised mortality risks ''40% would delay treatment when CD4-cell counts drop below 200, even if waiting boosted mortality risks by up to 10%
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Don’t miss our latest news! Sign up today for our free newsletter.
Plus: Featured Video